Furthermore, the use of nanoparticles in drug delivery presents innovative avenues in cancer treatment, such as vaccines enclosed within synthetic nanoparticles and nanoformulations designed to target glycoproteins or glycan-binding proteins [34,35,36], which could also be envisioned for future GLUT1-targeted therapy. The gene discussed is SLC2A1; the disease is cancer.